Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of PI-88 With Dacarbazine in Patients With Metastatic Melanoma

NCT00130442 is registered in ClinicalTrials.gov with Cellxpert Biotechnology Corp. as lead sponsor.

NCT NCT00130442
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00130442 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of PI-88 With Dacarbazine in Patients With Metastatic Melanoma
Lead sponsor
Cellxpert Biotechnology Corp.
Phase
Phase 2
Overall status
Completed
Start date
June 30, 2005
Completion date
October 31, 2010
Enrollment
134 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

melanoma